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 2 
ABSTRACT. 14 
Conformational conversion of the cellular prion protein, PrP
C
, into the abnormally 15 
folded isoform of prion protein, PrP
Sc
, which leads to marked accumulation of PrP
Sc
 16 
in brains, is a key pathogenic event in prion diseases, a group of fatal 17 
neurodegenerative disorders caused by prions. However, the exact mechanism of 18 
PrP
Sc
 accumulation in prion-infected neurons remains unknown. We recently 19 
reported a novel cellular mechanism to support PrP
Sc
 accumulation in prion-infected 20 
neurons, in which PrP
Sc
 itself promotes its accumulation by evading the cellular 21 
inhibitory mechanism, which is newly identified in our recent study. We showed that 22 
the VPS10P sorting receptor sortilin negatively regulates PrP
Sc
 accumulation in 23 
prion-infected neurons, by interacting with PrP
C
 and PrP
Sc
 and trafficking them to 24 
lysosomes for degradation. However, PrP
Sc
 stimulated lysosomal degradation of 25 
sortilin, disrupting the sortilin-mediated degradation of PrP
C
 and PrP
Sc
 and 26 
eventually evoking further accumulation of PrP
Sc
 in prion-infected neurons. These 27 
findings suggest a positive feedback amplification mechanism for PrP
Sc
 accumulation 28 
in prion-infected neurons.  29 
 30 
KEYWORDS. Prions, prion protein, sortilin, sorting, VPS10P sorting receptor, 31 
protein degradation, lysosome.  32 
  33 
 3 
Introduction 34 
Prions are causative agents of prion diseases, a group of fatal neurodegenerative disorders 35 
including Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy and 36 
scrapie in animals.
1
 They are widely believed to consist of the abnormally folded, 37 
amyloidogenic isoform of prion protein, designated PrP
Sc
.
1
 PrP
Sc
 is produced through 38 
conformational conversion of the cellular prion protein, PrP
C
, by unknown mechanisms.
1
 39 
PrP
C
 is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein expressed 40 
most abundantly in brains, particularly by neurons.
2
 The constitutive conversion of PrP
C
 41 
into PrP
Sc
 leads to accumulation of PrP
Sc
 in brains. We and others have shown that the 42 
conversion of PrP
C
 into PrP
Sc
 is a key pathogenic event in prion disease, by demonstrating 43 
that mice devoid of PrP
C
 neither developed the disease nor propagated prions or 44 
accumulated PrP
Sc
 in their brains after intracerebral inoculation with prions.
3-6
 Most 45 
pathogens usually evade host defense mechanisms to propagate themselves in their hosts. 46 
However, the host defense mechanism against prions to suppress prion propagation, or 47 
PrP
Sc
 accumulation, remains unknown.  48 
 The vacuolar protein sorting-10 protein (VPS10P)-domain receptors, including 49 
sortilin, SorLA, SorCS1, SorCS2 and SorCS3, are multi-ligand type I transmembrane 50 
proteins abundantly expressed in brains and involved in neuronal function and viability.
7, 8
 51 
They function as a cargo receptor to deliver a number of cargo proteins to their subcellular 52 
compartments through the VPS10P domain in the extracellular luminal N-terminus.
7, 8
 53 
Accumulating lines of evidence indicate that altered VPS10P receptor-mediated trafficking 54 
 4 
could be involved in the pathogenesis of neurodegenerative disorders, including 55 
Alzheimer’s disease9-12 and frontotemporal lobar degeneration.13 Sortilin mediates 56 
intracellular trafficking of the amyloid precursor protein (APP)-cleaving enzyme BACE1
14
 57 
and the neurotrophic factor receptors Trks.
15
 SorLA and SorCS1 are involved in APP 58 
transport.
9, 11
  59 
We recently reported that sortilin negatively regulates PrP
Sc
 accumulation by sorting 60 
PrP
C
 and PrP
Sc
 to lysosomes for degradation, and that PrP
Sc
 accumulation itself impairs the 61 
sotrtilin-mediated degradation of PrP
C
 and PrP
Sc
 by stimulating lysosomal degradation of 62 
sortilin, thereby evoking further accumulation of PrP
Sc
 in prion-infected cells.
16
 These 63 
findings suggest that the sortilin-mediated lysosomal degradation of PrP
C
 and PrP
Sc
 could 64 
be a host defense mechanism against prions, and that prions, or PrP
Sc
, could propagate in 65 
infected neurons by evading the sortilin-mediated defense mechanism by inducing 66 
lysosomal degradation of sortilin.  67 
 68 
Sortilin is a negative regulator for PrP
Sc
 accumulation  69 
We found that PrP
C
 directly interacts with sortilin, but not with other VPS10P molecules, 70 
on the plasma membrane in PrP
C
-overexpressing neuroblastoma N2a cells, designated 71 
N2aC24 cells.
16
 The interaction of both molecules was also confirmed in mouse brain 72 
homogenates.
16
 SiRNA-mediated knockdown of sortilin increased PrP
Sc
 in prion-infected 73 
N2aC24L1-3 cells, which are N2aC24 cells persistently infected with 22L scrapie prions.
16
 74 
In contrast, overexpression of sortilin in N2aC24L1-3 cells decreased PrP
Sc
.
16
 We also 75 
 5 
showed that sortilin-knockout mice had accelerated prion disease caused by early 76 
accumulation of PrP
Sc
 in their brains after infection with RML scrapie prions.
16
 These 77 
results indicate that sortilin could negatively regulate PrP
Sc
 accumulation in prion-infected 78 
cells and mice. 79 
 80 
Sortilin traffics PrP
C
 to non-raft domains and to late endosomes/lysosomes  81 
PrP
C
 is synthesized in the endoplasmic reticulum (ER) and trafficked to the plasma 82 
membrane through the Golgi apparatus.
17
 PrP
C
 undergoes several posttranslational 83 
modifications during its biosynthesis, including cleavage of the N-terminal signal peptide, 84 
removal of the C-terminal peptide for attachment of a GPI anchor at the C-terminus and 85 
formation of a disulfide bond at the C-terminal domain in the ER, and addition of two core 86 
N-linked oligosaccharides at the C-terminal domain in the ER that are further modified in 87 
the ER and then in the Golgi apparatus.
17
 Like other GPI-anchored proteins, PrP
C
 is 88 
predominantly located at raft domains and, to a lesser extent, at non-raft domains.
16, 17
 After 89 
internalization, some PrP
C
 molecules are delivered back to the plasma membrane directly or 90 
indirectly via the recycling endosome compartments and others are transported to 91 
lysosomes for degradation.
18
 Copper and zinc stimulate endocytosis of PrP
C
 by binding to 92 
histidine residues in the octapeptide repeat (OR) region located in the N-terminal 93 
domain.
19-21
 It has been postulated that PrP
C
 interacts with an as yet unidentified raft 94 
molecule via the N-terminal domain including the OR region, thereby being retained at raft 95 
domains.
20
 The binding of copper or zinc to the OR region causes structural changes in the 96 
 6 
N-terminal interacting region of PrP
C
, thereby PrP
C
 leaves raft domains to non-raft domains 97 
to be endocytosed via the clathrin-dependent pathway.
20
 Low-density lipoprotein 98 
receptor-related protein 1 has been reported to be involved in the clathrin-dependent 99 
endocytosis of PrP
C
.
22
 The clathrin-independent pathways including caveolae, which is 100 
considered to be formed by clustering raft domains, or caveolae-like domains have been 101 
also reported to mediate the endocytosis of PrP
C
.
18
 102 
We found that sortilin was predominantly located at non-raft domains in 103 
prion-uninfected N2aC24 cells.
16
 Sortilin knockout caused marked shift in localization of 104 
PrP
C
 from non-raft domains to raft domains in N2aC24 cells and mouse brains.
16
 These 105 
findings suggest that sortilin could function to recruit PrP
C
 from raft domains to non-raft 106 
domains. We also found that, after internalization, PrP
C
 was transported to both late 107 
endosomes and recycling endosomes in N2aC24 cells.
16
 However, PrP
C
 was preferentially 108 
transported to recycling endosomes with reduced localization at late endosomes/lysosomes 109 
in sortilin-knockdown and -knockout N2aC24 cells,
16
 indicating that sortilin also could 110 
function as an endocytic receptor for PrP
C
 at non-raft domains to be sent to lysosomes for 111 
degradation (Fig. 1A). Consistent with this, sortilin-deficient N2aC24 cells showed higher 112 
PrP
C
 on their plasma membranes than control N2aC24 cells.
16
 Sortilin-knockout mice also 113 
showed higher PrP
C
 in their brains compared to WT mice.
16
 Moreover, inhibition of 114 
lysosomal enzymes by NH4Cl increased PrP
C
 markedly in N2aC24 cells, but only slightly 115 
in sortilin-knockout N2aC24 cells.
16
  116 
The plasma membrane or raft domains are considered to be major sites for the 117 
 7 
conversion of PrP
C
 into PrP
Sc
,
23
 although the exact site of PrP
Sc
 production remains 118 
controversial. It is thus likely that sortilin could negatively regulate PrP
Sc
 accumulation by 119 
reducing PrP
C
 on the plasma membrane, particularly at raft domains through recruiting 120 
PrP
C
 to non-raft domains from raft domains and sorting it to the late endosome/lysosome 121 
protein degradation pathway.  122 
 123 
Sortilin is involved in degradation of PrP
Sc
 124 
We also found that sortilin could function to direct PrP
Sc
 for degradation.
16
 Sortilin 125 
interacted with PrP
Sc
 in prion-infected N2aC24L1-3 cells.
16
 Sortilin-knockout significantly 126 
slowed down the degradation of PrP
Sc
 in N2aC24 cells infected with RML or 22L prions.
16
 127 
PrP
Sc
 is found at various intracellular compartments, including the plasma membrane, 128 
various endosomal compartments such as early and late endosomes, recycling endosomes, 129 
and lysosomes, and the Golgi apparatus.
18
 Enzymatic release of PrP
C
 from the plasma 130 
membrane by phosphoinositide-specific phospholipase C was shown to reduce PrP
Sc
 in 131 
infected cells,
24
 and formation of PrP
Sc
 was inhibited by lowered temperature,
25
 which 132 
blocks the endocytosis and internalization of PrP
C
. These suggest that the conversion of 133 
PrP
C
 into PrP
Sc
 might occur at the plasma membrane, where exogenous PrP
Sc
 is likely to 134 
first contact endogenous PrP
C
, or after its internalization in the endosomal compartment. 135 
Internalized PrP
Sc
 could also undergo retrograde transport to the Golgi apparatus and/or to 136 
the ER,
26, 27
 where the transported PrP
Sc
 might trigger the conversion of PrP
C
 into PrP
Sc
. 137 
PrP
Sc
 molecules on the plasma membrane are trafficked to lysosomes for degradation via 138 
 8 
the endolysosomal pathway.
28, 29
 The PrP
Sc
 retrogradely transported to the Golgi apparatus 139 
are subjected to Golgi quality control and trafficked to lysosomes for degradation.
27
 Sortilin 140 
localizes in para-nuclear vesicles, in the trans-Golgi network, and on the plasma 141 
membrane.
30, 31
 It is thus possible that sortilin could be involved in both degradation 142 
trafficking pathways of PrP
Sc
. However, sortilin and PrP
Sc
 molecules differed in their 143 
microdomain localization on the plasma membrane in N2aC24L1-3 cells. Sortilin was 144 
predominantly detected in non-raft fractions while PrP
Sc
 was exclusively located in raft 145 
fractions (Fig. 1B).
16
 Therefore, the sortilin-mediated lysosomal degradation of PrP
Sc
 146 
located on the plasma membrane might be a minor event.  147 
 148 
PrP
Sc
 stimulates degradation of sortilin in lysosomes 149 
Interestingly, we found that sortilin was markedly reduced in both prion-infected cells and 150 
mouse brains, and that the reduced sortilin levels in prion-infected cells were recovered by 151 
treatment with lysosomal inhibitors but not with proteasomal inhibitor.
16
 These findings 152 
suggest that sortilin is increasingly degraded in lysosomes in prion-infected cells. We also 153 
found that PrP
Sc
 accumulation preceded the reduction of sortilin in N2aC24 cells freshly 154 
infected with RML prions.
16
 Immunofluorescent staining showed that sortilin was barely 155 
detectable in PrP
Sc
-positive cells but still abundantly observed in PrP
Sc
-negative cells.
16
 It is 156 
thus likely that PrP
Sc
 produced after prion infection could stimulate sortilin degradation in 157 
lysosomes in a cell-autonomous fashion, and that the negative role of sortilin in PrP
Sc
 158 
accumulation could be impaired in prion-infected cells, therefore PrP
Sc
 progressively 159 
 9 
accumulates in prion-infected neurons.  160 
 161 
Conclusions  162 
We presented a novel accumulation mechanism of PrP
Sc
 through degradation of sortilin. 163 
Sortilin could form the host defense mechanism against prions, by functioning to sort PrP
C
 164 
and PrP
Sc
 to the late endosomal/lysosomal compartments for degradation (Fig. 1A, B). 165 
Conversely, PrP
Sc
 itself stimulates degradation of sortilin in lysosomes, reducing sortilin 166 
levels and impairing its defense function against prions. As a result, PrP
C
 is increasingly 167 
converted to PrP
Sc
, and PrP
Sc
 degradation is delayed, and eventually PrP
Sc
 progressively 168 
accumulates in prion-infected cells (Fig. 1B). Accelerating the sortilin-mediated lysosomal 169 
degradation of PrP
C
 and PrP
Sc
 might be beneficial for treatment of prion diseases. 170 
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Figure Legends 278 
Figure 1. A model of the sortilin-mediated intracellular trafficking of PrP
C
 and PrP
Sc
 279 
in prion-uninfected and infected neurons. (A) Sortilin-dependent and -independent 280 
endocytosis of PrP
C
 in uninfected neurons. Sortilin mediates endocytosis of PrP
C
 on the 281 
plasma membrane (PM), particularly at non-raft domains, via the clathrin-dependent 282 
pathway to early endosomes (EE) and then traffics it to late endosomes/lysosomes (LE/Lys) 283 
for degradation. Other PrP
C
 molecules are trafficked either to LE/Lys for degradation or to 284 
the recycling endosome (RE) pathway in a sortilin-independent way. There also might be 285 
sortilin-dependent and -independent trafficking pathways from the Golgi apparatus (GA) to 286 
LE/Lys for degradation. (B) Intracellular trafficking of PrP
C
 and PrP
Sc
 in prion-infected 287 
neurons. Prion infection stimulates lysosomal degradation of sortilin via an unknown 288 
mechanism, thereby impairing the sortilin-mediated trafficking of PrP
C
 and PrP
Sc
 to LE/Lys 289 
for degradation. As a result, PrP
C
 and PrP
Sc
 are increased at raft domains and endocytosed 290 
via the sortilin-independent pathway to RE, causing accumulation of PrP
Sc
 and increasing 291 
conversion of PrP
C
 into PrP
Sc
 in prion-infected neurons. PrP
Sc
 could undergo retrograde 292 
transport to the GA. However, sortilin might also be functionally impaired in the GA, 293 
thereby being unable to traffic PrP
Sc
 in the GA to LE/Lys for degradation. The decreased 294 
degradation of PrP
Sc
 in LE/Lys and the increased conversion of PrP
C
 into PrP
Sc
 in raft 295 
domains or RE could both contribute to the constitutive production of PrP
Sc
 in 296 
prion-infected neurons. Dashed arrows indicate restricted trafficking.  297 
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